PEG-Interferon alfa-2b plus Ribavirin-Behandlung bei chronischer Hepatitis C

被引：0
|
作者：
机构：
来源：
Monatsschrift Kinderheilkunde | 2005年 / 153卷 / 12期
关键词：
D O I：
10.1007/s00112-005-1265-4
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1192 / 1193
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium
    Wong, JB
    Nevens, F
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2002, 65 (02): : 110 - 111
  • [22] Gene expression of cytoplasmic viral sensors and regulators involving innate immunity and resistance to PEG-interferon alfa-2B plus ribavirin treatment in chronic hepatitis C
    Asahina, Yasuhiro
    Izumi, Namiki
    Hirayama, Itsuko
    Sato, Mitsuaki
    Tanaka, Tomohiro
    Komatsu, Nobutoshi
    Umeda, Naoki
    Hosokawa, Takanori
    Ueda, Ken
    Nakanishi, Hiroyuki
    Tsuchiya, Kaoru
    Itakura, Jun
    Kurosaki, Masayuki
    Uchihara, Masakatsu
    Miyake, Shozo
    HEPATOLOGY, 2007, 46 (04) : 345A - 345A
  • [23] Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation
    Lodato, F.
    Berardi, S.
    Gramenzi, A.
    Mazzella, G.
    Lenzi, M.
    Morelli, M. C.
    Tame, M. R.
    Piscaglia, F.
    Andreone, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (04) : 450 - 457
  • [24] ENDOGENOUS ERYTHROPOIETIN RESPONSE AND PREDICTIVE FACTORS FOR ANEMIA DURING TREATMENT WITH PEG-INTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS
    van Vlerken, L. G.
    van Soest, H.
    Janssen, M. P.
    Boland, G. J.
    Drenth, J. P. H.
    Burger, D. M.
    Siersema, P. D.
    van Erpecum, K. J.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S103 - S103
  • [25] THERAPEUTIC RESPONSE TO PEG-INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C
    Harja-Alexa, Ioana-Alina
    Luca, Mihaela-Catalina
    Manciuc, Carmen Doina
    Vata, A.
    Badescu, Aida
    Hurmuzache, M. E.
    Ciocan, Alexandra Mirela
    Hunea, Ioana Maria
    Trofin, Felicia
    Iancu, Luminita Smaranda
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2019, 123 (04): : 615 - 622
  • [26] Endogenous Erythropoietin Response and Predictive Factors for Anemia During Treatment With PEG-Interferon Alfa-2B and Ribavirin in Chronic Hepatitis C Patients
    van Vlerken, Lotte G.
    van Soest, Hanneke
    Janssen, Mart P.
    Boland, Greet J.
    Drenth, Joost P. H.
    Burger, David M.
    Siersema, Peter D.
    Van Erpecum, Karel J.
    GASTROENTEROLOGY, 2010, 138 (05) : S842 - S842
  • [27] 24 weeks of treatment with peg-interferon alfa-2b plus ribavirin in patients infected with HCV genotype 2 and 3.
    Wiegand, J
    HEPATOLOGY, 2002, 36 (04) : 360A - 360A
  • [28] Two doses of PEG-Interferon alfa-2b plus rivabirin in genotype 1 naive patients with chronic hepatitis
    Buti, M
    Lurie, Y
    Sanchez, F
    Valdes, A
    Martell, M
    Esteban, R
    Guardia, J
    JOURNAL OF HEPATOLOGY, 2002, 36 : 102 - 102
  • [29] Treatment outcome in patients with chronic hepatitis C treated with different pegylated(PEG) interferon alfa-2b plus ribavirin regimens
    Zhang, YT
    Levendoglu, H
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (09): : 1033 - 1033
  • [30] Peg-intron plus ribavirin vs. interferon alfa-2b plus ribavirin in naive patients with chronic C hepatitis: Preliminary results.
    Gaetano, S
    Vincenzina, F
    Emilio, P
    Mario, C
    Gioachino, A
    HEPATOLOGY, 2002, 36 (04) : 571A - 571A
12345